These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 20186724)

  • 1. An alternative phase II/III design for continuous endpoints.
    Huang WS; Liu JP; Hsiao CF
    Pharm Stat; 2011; 10(2):105-14. PubMed ID: 20186724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
    Kimani PK; Stallard N; Hutton JL
    Stat Med; 2009 Mar; 28(6):917-36. PubMed ID: 19152231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting population entering phase III trials: a new stratified adaptive phase II design.
    Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
    Stat Med; 2011 Apr; 30(8):801-11. PubMed ID: 21432875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
    Wang SJ; Hung HM; O'Neill R
    J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seamless Phase II/III combination study through response adaptive randomization.
    Wang L; Cui L
    J Biopharm Stat; 2007; 17(6):1177-87. PubMed ID: 18027224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
    Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
    Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several.
    Kelly PJ; Stallard N; Todd S
    J Biopharm Stat; 2005; 15(4):641-58. PubMed ID: 16022169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.
    Masaki N; Koyama T; Yoshimura I; Hamada C
    J Biopharm Stat; 2009 Jul; 19(4):721-31. PubMed ID: 20183436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests.
    Polley MY; Cheung YK
    Biometrics; 2008 Mar; 64(1):232-41. PubMed ID: 17573866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing a series of decision-theoretic phase II trials in a small population.
    Hee SW; Stallard N
    Stat Med; 2012 Dec; 31(30):4337-51. PubMed ID: 22927289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information.
    Stallard N
    Stat Med; 2010 Apr; 29(9):959-71. PubMed ID: 20191605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A composite design for transition from a preliminary to a full-scale study.
    Lachin JM; Younes N
    Stat Med; 2007 Nov; 26(27):5014-32. PubMed ID: 17577245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curtailed two-stage designs with two dependent binary endpoints.
    Chen CM; Chi Y
    Pharm Stat; 2012; 11(1):57-62. PubMed ID: 22162348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical analysis for two-stage seamless design with different study endpoints.
    Chow SC; Lu Q; Tse SK
    J Biopharm Stat; 2007; 17(6):1163-76. PubMed ID: 18027223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A seamless phase II/III design with sample-size re-estimation.
    Bischoff W; Miller F
    J Biopharm Stat; 2009 Jul; 19(4):595-609. PubMed ID: 20183428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On group sequential designs comparing two binomial proportions.
    Kepner JL
    J Biopharm Stat; 2010 Jan; 20(1):145-59. PubMed ID: 20077254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exact two-stage designs for phase II activity trials with rank-based endpoints.
    Wilding GE; Shan G; Hutson AD
    Contemp Clin Trials; 2012 Mar; 33(2):332-41. PubMed ID: 22074983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.